The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid

Rui Zhu, Jennifer J. Kiser, Heiner I. Seifart, Cedric J. Werely, Charles D. Mitchell, David Z. D'Argenio, Courtney V. Fletcher

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection. Plasma concentration-time measurements of isoniazid from 151 infants (starting at 3-4 months of age) receiving isoniazid 10 to 20 mg/kg/d orally during the course of the 24-month study were incorporated in a population analysis along with NAT2 genotype, body weight, age, and sex. The results showed a different NAT2 enzyme maturation profile for each of the 3 acetylation groups, with the 70-kg body weight-normalized typical apparent clearance for the fast and intermediate acetylators increasing from 14.25 L/h and 10.88 L/h at 3 months of age to 22.84 L/h and 15.58 L/h at 24 months of age, respectively, with no significant change in the apparent clearance of the slow group during this period. A hypothesis is proposed to explain the genotype-dependent enzyme maturation processes for the NAT2 enzyme.

Original languageEnglish (US)
Pages (from-to)511-519
Number of pages9
JournalJournal of Clinical Pharmacology
Issue number4
StatePublished - Apr 2012


  • Infants
  • enzyme maturation
  • genetic polymorphism
  • pharmacogenetics
  • population pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid'. Together they form a unique fingerprint.

Cite this